Digital Health & AI Innovation

SHERIDAN, WYOMING – July 25, 2025 – Philips has secured FDA 510(k) clearance for its next-generation UroNav platform, reinforcing the company’s leadership in image-guided interventions for prostate cancer. The upgraded UroNav 2.0 system is designed to unify MR/ultrasound fusion imaging with advanced workflow integration, helping clinicians deliver more accurate, less invasive, and highly personalized focal therapies.

SHERIDAN, WYOMING – July 25, 2025 – Philips and Radboud university medical center (Radboudumc) are conducting one of the first large-scale studies to explore the impact of prolonged physical activity on atrial fibrillation, leveraging wearable monitoring technology during the 4Days Marches in the Netherlands. The collaboration combines clinical expertise with cutting-edge sensor technology to better understand how exercise influences this widespread heart rhythm disorder.

Continuous Monitoring for Deeper Insight into Atrial Fibrillation

SHERIDAN, WYOMING – July 25, 2025 – Philips Foundation has announced the results of its 2024 activities in a newly published Annual Report, celebrating a milestone year that brought quality healthcare access to 46.5 million people globally—up from 28 million in 2023. The results mark a significant stride toward the Foundation’s 2030 goal of reaching 100 million underserved individuals each year.

Strategic Projects and Investments Drive Expansion

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) has confirmed the exchange ratio for its 2024 dividend, announcing a share-based conversion rate of one new common share for every 23.6353 existing shares. The ratio was determined based on the volume-weighted average price of Philips shares traded on Euronext Amsterdam across May 30, June 2, and June 3, 2025, which stood at EUR 20.0600.

SHERIDAN, WYOMING – July 25, 2025 – Maryland continues to assert itself as a national leader in life sciences, driven by a dynamic workforce, strong academic institutions, and expanding industry infrastructure. With the Washington, D.C.–Baltimore area ranking among the top six U.S. regions for R&D and manufacturing talent, the state is attracting significant investment and fostering sustainable growth across biotech and pharmaceutical sectors.

Talent-Driven Advantage for Life Sciences Expansion

SHERIDAN, WYOMING – July 21, 2025 – Sensei, the practice and patient management brand of Carestream Dental, has announced a strategic integration with DentalMonitoring, a global leader in AI-powered remote monitoring solutions for orthodontics. The collaboration, revealed during the 2025 American Association of Orthodontists (AAO) Annual Session in Philadelphia, marks a pivotal move in expanding digital orthodontic care with advanced clinical oversight, enhanced operational efficiency, and increased patient engagement.

SHERIDAN, WYOMING – July 21, 2025 – Carestream Dental showcased its latest innovations in clinical productivity and patient care at IDS 2025 in Cologne, Germany, under the theme “Delivering What’s Next.” The company’s presentation at Hall 11.1, C010, reflected its longstanding commitment to advancing dental technology and empowering practitioners worldwide.

Innovation That Builds on a Century of Leadership

SHERIDAN, WYOMING – July 21, 2025 – The latest generation of biotech unicorns is navigating a challenging financial landscape, as AI-powered drug discovery ventures encounter tight investment conditions and a shrinking pool of exit opportunities. While their billion-dollar valuations once promised swift IPOs, today's market demands more strategic flexibility, operational discipline, and differentiated technologies.

Valuations Under Pressure in a Binary Outcome Industry

SHERIDAN, WYOMING – July 21, 2025 – Wellhub, a global corporate wellbeing platform, has announced today the signing of a definitive agreement to acquire Urban Sports Club, a leading European provider of corporate fitness programs and consumer wellness offerings. This strategic acquisition positions Wellhub to strengthen its presence in Europe while enhancing its portfolio of wellbeing solutions for corporate clients and their employees.

Expanding Reach in a Growing Corporate Wellbeing Market

SHERIDAN, WYOMING – July 8, 2025 – In a landmark agreement that underscores the growing convergence of artificial intelligence and drug discovery, Tokyo-based Chugai Pharmaceutical has entered into a multi-phase research collaboration with Singapore-headquartered biotech Gero to target age-related diseases using AI-driven insights. The deal could exceed $1 billion in total value, positioning both companies at the forefront of longevity-focused pharmaceutical innovation.

AI-Powered Discovery for High-Impact Biologics